AbbVie (ABBV) delivered impressive FY2025 results with revenue of $61.2B, representing approximately 10% growth year-over-year as the company's immunology successors -- Skyrizi (risankizumab) and Rinvoq (upadacitinib) -- rapidly offset the Humira biosimilar headwind. Skyrizi is on track to become on
Access the complete analysis, financial model, price target breakdown, and risk factors.
Read Full Report →2 free reads per day · No credit card required